WO2008034124A3 - Targeted polymeric prodrugs containing multifunctional linkers - Google Patents

Targeted polymeric prodrugs containing multifunctional linkers Download PDF

Info

Publication number
WO2008034124A3
WO2008034124A3 PCT/US2007/078600 US2007078600W WO2008034124A3 WO 2008034124 A3 WO2008034124 A3 WO 2008034124A3 US 2007078600 W US2007078600 W US 2007078600W WO 2008034124 A3 WO2008034124 A3 WO 2008034124A3
Authority
WO
WIPO (PCT)
Prior art keywords
containing multifunctional
prodrugs containing
polymeric prodrugs
multifunctional linkers
targeted polymeric
Prior art date
Application number
PCT/US2007/078600
Other languages
French (fr)
Other versions
WO2008034124A2 (en
Inventor
Hong Zhao
Maria Belen Rubio
Prasanna Reddy
Original Assignee
Enzon Pharmaceuticals Inc
Hong Zhao
Maria Belen Rubio
Prasanna Reddy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc, Hong Zhao, Maria Belen Rubio, Prasanna Reddy filed Critical Enzon Pharmaceuticals Inc
Priority to JP2009528519A priority Critical patent/JP2010503708A/en
Priority to MX2009002855A priority patent/MX2009002855A/en
Priority to AU2007296056A priority patent/AU2007296056B2/en
Priority to BRPI0716812-8A priority patent/BRPI0716812A2/en
Priority to CA002662981A priority patent/CA2662981A1/en
Priority to EP07842578.2A priority patent/EP2073820A4/en
Publication of WO2008034124A2 publication Critical patent/WO2008034124A2/en
Publication of WO2008034124A3 publication Critical patent/WO2008034124A3/en
Priority to IL197517A priority patent/IL197517A0/en
Priority to US12/402,839 priority patent/US8367065B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/10—Polyimides; Polyester-imides; Polyamide-imides; Polyamide acids or similar polyimide precursors
    • C08G73/12—Unsaturated polyimide precursors
    • C08G73/121—Preparatory processes from unsaturated precursors and polyamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
    • C08G64/20—General preparatory processes
    • C08G64/26—General preparatory processes using halocarbonates
    • C08G64/28—General preparatory processes using halocarbonates and phenols
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polyethers (AREA)

Abstract

The present invention provides single chain antibody-directed polymeric prodrugs containing multifunctional linkers. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed.
PCT/US2007/078600 2006-09-15 2007-09-15 Targeted polymeric prodrugs containing multifunctional linkers WO2008034124A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2009528519A JP2010503708A (en) 2006-09-15 2007-09-15 Targeted polymer prodrugs containing multifunctional linkers
MX2009002855A MX2009002855A (en) 2006-09-15 2007-09-15 Targeted polymeric prodrugs containing multifunctional linkers.
AU2007296056A AU2007296056B2 (en) 2006-09-15 2007-09-15 Targeted polymeric prodrugs containing multifunctional linkers
BRPI0716812-8A BRPI0716812A2 (en) 2006-09-15 2007-09-15 PRO POLYMERIC DRUGS DIRECTED CONTAINING MULTIFUNCTIONAL LEADERS
CA002662981A CA2662981A1 (en) 2006-09-15 2007-09-15 Targeted polymeric prodrugs containing multifunctional linkers
EP07842578.2A EP2073820A4 (en) 2006-09-15 2007-09-15 Targeted polymeric prodrugs containing multifunctional linkers
IL197517A IL197517A0 (en) 2006-09-15 2009-03-10 Targeted polymeric prodrugs containing multifunctional linkers and methods of use thereof
US12/402,839 US8367065B2 (en) 2006-09-15 2009-03-12 Targeted polymeric prodrugs containing multifunctional linkers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84494306P 2006-09-15 2006-09-15
US60/844,943 2006-09-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/402,839 Continuation US8367065B2 (en) 2006-09-15 2009-03-12 Targeted polymeric prodrugs containing multifunctional linkers

Publications (2)

Publication Number Publication Date
WO2008034124A2 WO2008034124A2 (en) 2008-03-20
WO2008034124A3 true WO2008034124A3 (en) 2008-08-07

Family

ID=39184644

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/078600 WO2008034124A2 (en) 2006-09-15 2007-09-15 Targeted polymeric prodrugs containing multifunctional linkers

Country Status (11)

Country Link
EP (1) EP2073820A4 (en)
JP (1) JP2010503708A (en)
KR (1) KR20090057383A (en)
CN (1) CN101541332A (en)
AU (1) AU2007296056B2 (en)
BR (1) BRPI0716812A2 (en)
CA (1) CA2662981A1 (en)
IL (1) IL197517A0 (en)
MX (1) MX2009002855A (en)
RU (1) RU2009114154A (en)
WO (1) WO2008034124A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027603T2 (en) 2007-04-20 2016-10-28 Sigma-Tau Rare Disease Ltd Stable recombinant adenosine deaminase
WO2009141823A2 (en) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases
WO2009141826A2 (en) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases
EP2288261A4 (en) * 2008-05-23 2013-09-25 Enzon Pharmaceuticals Inc Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
MY151184A (en) 2008-07-23 2014-04-30 Hanmi Science Co Ltd A polypeptide complex comprising non-peptidyl polymer having three functional ends
CN102231950A (en) * 2008-11-17 2011-11-02 安龙制药公司 Releasable polymeric lipids for nucleic acids delivery systems
US20110230420A1 (en) * 2008-11-17 2011-09-22 Enzon Pharmaceuticals, Inc. Releasable conjugates for nucleic acids delivery systems
EP2525829A1 (en) * 2010-01-22 2012-11-28 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US20130018010A1 (en) * 2010-04-16 2013-01-17 Enzon Pharmaceuticals, Inc. Polymeric conjugates of adenine nucleoside analogs
JP5113958B2 (en) 2010-06-11 2013-01-09 独立行政法人科学技術振興機構 Drug multimer fine particles and method for producing the same
EP2646818A4 (en) * 2010-11-30 2016-09-21 Univ Illinois Silica nanoparticle agent conjugates
CN103045720B (en) * 2011-10-17 2014-08-20 格诺思博生物科技(上海)有限公司 Targeting molecule for detecting pathogenic cell and application thereof
CN104244988A (en) 2012-03-05 2014-12-24 雷蒙特亚特特拉维夫大学有限公司 Polymers having therapeutically active agents conjugated thereto, processes of preparing same and uses thereof
CN102746316B (en) * 2012-06-26 2015-04-15 济南精合医药科技有限公司 An m-nitroarylmethoxy camptothecin anoxic activation prodrug for antitumor drugs
CN102731518B (en) * 2012-06-26 2014-12-03 济南精合医药科技有限公司 O-nitro aryl methoxycamptothecine anoxic activated prodrug used for antitumor drug
KR102320753B1 (en) * 2013-10-04 2021-11-02 프로린크스 엘엘시 Slow-release conjugates of sn-38
CN105764503A (en) 2013-10-15 2016-07-13 西雅图基因公司 PEGylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
GB201414098D0 (en) 2014-08-08 2014-09-24 Illumina Cambridge Ltd Modified nucleotide linkers
SG11201701384XA (en) 2014-10-14 2017-03-30 Polytherics Ltd Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
ES2960741T3 (en) * 2014-10-24 2024-03-06 Abzena Uk Ltd Conjugates and conjugation reagents
JP6570034B2 (en) * 2014-11-26 2019-09-04 日本化薬株式会社 Novel glutamic acid derivatives and uses thereof
CN105641708A (en) * 2014-12-04 2016-06-08 上海中医药大学附属普陀医院 Polypeptide modified poly(oligo(ethylene glycol) methacrylate-co-bufalin) nano preparation, and preparation method thereof
US11571480B2 (en) 2015-08-11 2023-02-07 Coherent Biopharma I, Limited Multi-ligand drug conjugates and uses thereof
EP3165532B1 (en) 2015-11-03 2018-12-19 Industrial Technology Research Institute Auristatin derivatives, linker-drugs and ligand-drug conjugates
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
CA3006000A1 (en) 2015-12-04 2017-06-08 Seattle Genetics, Inc. Conjugates of quaternized tubulysin compounds
CN109843919A (en) 2016-03-25 2019-06-04 西雅图基因公司 The method for being used to prepare the agent-linker and its intermediate of Pegylation
CN107375288B (en) * 2016-05-16 2019-08-23 博瑞生物医药（苏州）股份有限公司 The polymerization target anticancer conjugate of multi-arm
CN106265683A (en) * 2016-09-14 2017-01-04 江南大学 A kind of preparation method with the pathogenic bacterium biomembrane new inhibitor wearing film targeting characteristic
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
IL269398B2 (en) 2017-03-24 2024-05-01 Seagen Inc Process for the preparation of glucuronide drug-linkers and intermediates thereof
ES2859473T3 (en) * 2017-04-21 2021-10-04 Bright Gene Bio Medical Tech Co Ltd Multi-arm Targeted Anticancer Conjugate
JP7231147B2 (en) * 2017-06-29 2023-03-01 国立大学法人東海国立大学機構 RNA introduction reagent and its use
CN118271394A (en) 2017-11-30 2024-07-02 思进公司 Process for the preparation of pharmaceutical linker compounds
KR20200108002A (en) 2018-01-08 2020-09-16 리제너론 파마슈티칼스 인코포레이티드 Steroids and antibody-conjugates thereof
AU2019208024A1 (en) 2018-01-12 2020-08-13 Prolynx Llc Protocol for minimizing toxicity of combination dosages and imaging agent for verification
KR102141124B1 (en) 2018-01-30 2020-08-04 (주)바이오니아 Double-stranded Oligonucleotide Complex comprising Double― stranded miRNA and Uses thereof
WO2019192488A1 (en) * 2018-04-02 2019-10-10 北京键凯科技有限公司 Cell-penetrating peptide-multiarm polyethylene glycol-drug conjugate having targeting property and application thereof
JP2022513400A (en) * 2018-10-29 2022-02-07 メルサナ セラピューティクス インコーポレイテッド Cysteine-manipulated antibody with peptide-containing linker-drug conjugate
AU2019405358A1 (en) * 2018-12-17 2021-01-28 Remegen Co., Ltd. A linker for antibody-drug conjugates and its use
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
WO2022022354A1 (en) * 2020-07-28 2022-02-03 重庆阿普格雷生物科技有限公司 Polyethylene glycol conjugate drug synergist, preparation method therefor, and use thereof
WO2022022360A1 (en) * 2020-07-28 2022-02-03 重庆阿普格雷生物科技有限公司 Polyethylene glycol conjugate drug, and preparation method therfor and use thereof
WO2022161452A1 (en) * 2021-01-28 2022-08-04 南京桦冠生物技术有限公司 Conjugate and use thereof
WO2023138682A1 (en) * 2022-01-24 2023-07-27 北京桦冠生物技术有限公司 Conjugate and use thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US6214330B1 (en) * 1998-07-13 2001-04-10 Enzon, Inc. Coumarin and related aromatic-based polymeric prodrugs
US6303569B1 (en) * 1997-12-30 2001-10-16 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6331289B1 (en) * 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US20030096743A1 (en) * 2001-09-24 2003-05-22 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US6743908B2 (en) * 1997-04-30 2004-06-01 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US6777387B2 (en) * 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
US20040235773A1 (en) * 2003-04-13 2004-11-25 Hong Zhao Polymeric oligonucleotide prodrugs
US7011812B1 (en) * 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
US20060130160A1 (en) * 1999-12-08 2006-06-15 Serono Genetics Institute S.A. Full-length human cDNAs encoding potentially secreted proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2626654B2 (en) * 1990-03-31 1997-07-02 科学技術振興事業団 Targeting high molecular weight pharmaceutical compounds and intermediates thereof
US6251382B1 (en) * 1998-04-17 2001-06-26 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
MXPA03007392A (en) * 2001-02-20 2003-12-04 Enzon Inc Terminally-branched polymeric linkers and polymeric conjugates containing the same.
CN100475269C (en) * 2002-03-05 2009-04-08 北京键凯科技有限公司 Binding agent of hydrophilic polymer-glutamic acid oligopeptide and medicinal molecular, composition containing said binding agent and use thereof
ITMI20020951A1 (en) * 2002-05-06 2003-11-06 Univ Degli Studi Trieste MULTIFUNCTIONAL DERIVATIVES OF POLYETHYLENGLICLE THEIR PREPARATION AND USE
US7122189B2 (en) * 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US20040228831A1 (en) * 2003-05-15 2004-11-18 Belinka Benjamin A. Polymeric conjugates for tissue activated drug delivery
GB0411186D0 (en) * 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
US7365127B2 (en) * 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
JP4877225B2 (en) * 2005-02-18 2012-02-15 日油株式会社 Polyoxyalkylene derivatives

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US7011812B1 (en) * 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
US6331289B1 (en) * 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6743908B2 (en) * 1997-04-30 2004-06-01 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US6303569B1 (en) * 1997-12-30 2001-10-16 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6214330B1 (en) * 1998-07-13 2001-04-10 Enzon, Inc. Coumarin and related aromatic-based polymeric prodrugs
US20060130160A1 (en) * 1999-12-08 2006-06-15 Serono Genetics Institute S.A. Full-length human cDNAs encoding potentially secreted proteins
US6777387B2 (en) * 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
US20030096743A1 (en) * 2001-09-24 2003-05-22 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US20040235773A1 (en) * 2003-04-13 2004-11-25 Hong Zhao Polymeric oligonucleotide prodrugs

Also Published As

Publication number Publication date
CA2662981A1 (en) 2008-03-20
AU2007296056B2 (en) 2012-09-13
EP2073820A4 (en) 2014-07-16
IL197517A0 (en) 2009-12-24
RU2009114154A (en) 2010-10-20
BRPI0716812A2 (en) 2013-11-05
CN101541332A (en) 2009-09-23
EP2073820A2 (en) 2009-07-01
AU2007296056A1 (en) 2008-03-20
WO2008034124A2 (en) 2008-03-20
KR20090057383A (en) 2009-06-05
MX2009002855A (en) 2009-03-30
JP2010503708A (en) 2010-02-04

Similar Documents

Publication Publication Date Title
WO2008034124A3 (en) Targeted polymeric prodrugs containing multifunctional linkers
WO2008034123A3 (en) Polymeric conjugates containing positively-charged moieties
WO2006119295A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2008014008A3 (en) Compositions and methods for modulating angiogenesis
WO2008013589A3 (en) Treatment of ras-expressing tumors
WO2008046911A3 (en) Novel human micrornas associated with cancer
WO2005097825A3 (en) Bmp-7 variants with improved properties
WO2006024018A3 (en) Compositions for treating nociceptive pain
WO2008034120A3 (en) Lysine-based polymeric linkers
WO2008097619A3 (en) Variant buttiauxella sp. phytases having altered properties
WO2007130697A8 (en) Anti-ephb4 antibodies and methods using same
WO2007081991A3 (en) Novel conjugated materials featuring proquinoidal units
WO2006023649A3 (en) Treatment of severe multiple sclerosis
WO2008060374A3 (en) Methods and compositions useful for diabetic wound healing
WO2007136969A3 (en) Bioabsorbable magnesium-reinforced polymer stents
TW200738270A (en) Method of treating depression using a TNFα antibody
PT2117521E (en) Transdermal delivery systems comprising bupivacaine
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2008120098A3 (en) Peptide prodrugs
WO2006089095A3 (en) Treating neurological disorders
WO2008066630A3 (en) Methods for reprogramming adult somatic cells and uses thereof
WO2006060189A3 (en) Curable silicone compositions incorporating a fluorescent detection system
WO2007089436A3 (en) Medical articles containing biodegradable polymers and acid-neutralizing cationic species
WO2006116773A3 (en) Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780042587.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07842578

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 575089

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 436/MUMNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2662981

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020097005134

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/002855

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009528519

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007296056

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007296056

Country of ref document: AU

Date of ref document: 20070915

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009114154

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007842578

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0716812

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090316